EUVIMEDEUVIMED entdecken
Crossref

NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer

Amélie Godard, Ghadir Kalot, Malorie Privat, Mohamed Bendellaa, Benoit Busser iD, K David Wegner, Franck Denat, Xavier Le Guével iD, Jean-Luc Coll iD, Catherine Paul, Ewen Bodio iD, Christine Goze iD und 1 weitere

Journal of Medicinal Chemistry · 13.04.2023 · 66 (7) · 5185-5195

DOI: 10.1021/acs.jmedchem.3c00100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.03.2023. Verfasst von Amélie Godard und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Chimie Moléculaire de l'Université de Bourgogne, Université de Bourgogne, CNRS UMR 6302, 21078 Dijon, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Ovarian Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Agence Nationale de la Recherche, Groupement des Entreprises Fran?aises dans la lutte contre le Cancer, Fondation pour la Recherche M?dicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalOvarian NeoplasmsFemaleHumansTrastuzumabFluorescent DyesBoron Compounds

Substanzen

TrastuzumabAntibodies, MonoclonalFluorescent DyesazaBDPBA compoundBoron Compounds

Autor:innen und Institutionen

  • Institut de Chimie Moléculaire de l'Université de Bourgogne, Université de Bourgogne, CNRS UMR 6302, 21078 Dijon, France.
  • Université Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences (IAB), 38000 Grenoble, France.
  • Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000 Paris, France.
  • LIIC, EA7269, Université de Bourgogne, 21000 Dijon, France.
  • Grenoble Alpes University Hospital (CHUGA), 38043 Grenoble, France.
  • Institut Universitaire de France (IUF) 75005 Paris, France.

ORCID-Profile: Benoit Busser, Xavier Le Guével, Jean-Luc Coll, Ewen Bodio, Christine Goze, Lucie Sancey

Förderung

  • Agence Nationale de la Recherche
  • Groupement des Entreprises Fran?aises dans la lutte contre le Cancer
  • Fondation pour la Recherche M?dicale
  • Soci?t? d'Acc?l?ration du Transfert de Technologies
  • Cancerop?le Auvergne Rh?ne Alpes CLARA
  • France Life Imaging

Zitieren

APA

Godard, A., Kalot, G., Privat, M., Bendellaa, M., Busser, B., Wegner, K. D., Denat, F., Le Guével, X., Coll, J. L., Paul, C., Bodio, E., Goze, C., & Sancey, L. (2023). NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer. Journal of Medicinal Chemistry, 66(7), 5185-5195. https://doi.org/10.1021/acs.jmedchem.3c00100

Vancouver

Godard A, Kalot G, Privat M, Bendellaa M, Busser B, Wegner KD, et al. NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer. Journal of Medicinal Chemistry. 2023;66(7):5185-5195. doi:10.1021/acs.jmedchem.3c00100

BibTeX
@article{Godard2023,
  author = {Godard, Amélie and Kalot, Ghadir and Privat, Malorie and Bendellaa, Mohamed and Busser, Benoit and Wegner, K David and Denat, Franck and Le Guével, Xavier and Coll, Jean-Luc and Paul, Catherine and Bodio, Ewen and Goze, Christine and Sancey, Lucie},
  title = {NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {7},
  pages = {5185--5195},
  doi = {10.1021/acs.jmedchem.3c00100}
}
Kostenlos starten →